EN DE
Watch Inhibrx Biosciences, Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Inhibrx Biosciences, Inc. (INBX) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Inhibrx Biosciences, Inc. stock $26.77, price $68.97, that is 61.2% below the price, quality 37 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US45720N1037

IB Inhibrx Biosciences, Inc. logo Thin data Nov 22, 2026

Inhibrx Biosciences, Inc.

INBX · US

Far too expensive (fair value 61% below the price) and weak company, but rising price: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Recent news mostly positive 
Negative equity (buybacks among others) 
Insiders bought $6.3M (6M) · sold $279,015 
Fair value $26.77 · Strongly overvalued 
Quality 37/100 
Weak Growth (revenue 5y −36.7 %/yr in USD) 
Negative free cash flow 
Trails peers (0/3) 
Narrow moat 23/100 · thin data
Thin data 
Estimate
Watch Inhibrx Biosciences, Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$141.84 $10.84 Fair Value $26.77 May 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.

How to read this chart

30‑month range $10.84 – $141.84 · fair‑value band $20.08 – $33.46 · the $68.97 price screens above the $26.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 22, 2026.

Follow Inhibrx Biosciences in your weekly email

Every Wednesday you see whether Inhibrx Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

Show moreShow less

Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.

Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Stock analysis

Inhibrx Biosciences, Inc. (INBX) currently trades at $68.97, while our estimate is $26.77, 61% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $20.08 (bear) to $33.46 (bull), the price of $68.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Inhibrx Biosciences, Inc. reported revenue of $1.3M in FY2025 versus $7.1M in FY2021, a compound −34.6%/yr. Reported net income was −$140M in FY2025.

Key figures

Market cap $1.1B Small · EPS (TTM) $-8.43 · Return on equity −1,774% · Return on assets (EBIT) −88.4% (5-year average) · Operating margin −6,287% · Revenue (TTM) $2.0M · Free cash flow −$130M · Net cash $17.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −61%, INBX screens richer than that median.

Fair Value

Bear $20.08 Fair Value $26.77 Bull $33.46
Price $68.97 · Downside -61.2%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 25
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors bought shares worth $6.3M, most recently on Oct 14, 2026. Over the same period, one person sold shares worth $279,015. Buying cluster

  • BuyMark LappeChief Executive Officer, Director3× since Sep 8, 2026: 45,040 shares, avg. $99.76$4.5MOct 14, 2026
  • BuyJon Faiz KayyemDirector3× since Sep 8, 2026: 15,000 shares, avg. $104.51$1.6MSep 23, 2026
  • SaleKimberly ManhardDirector2× since Sep 8, 2026: 2,500 shares, avg. $111.61$279,015Sep 15, 2026
  • BuyDouglas ForsythDirector2,500 shares at $114.65$286,625Sep 8, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−526.6% (2020) → −10,386.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

INBX screens overvalued: fair value 61% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Inhibrx Biosciences, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 856 stocks

Beats the industry median on 0/3 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −61.2% · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −95.6% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs INBX
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs INBX
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs INBX
argenx SE ARGX $925.70 $908.40 −2% vs INBX
CSL Limited CSL A$197.29 A$188.80 −4% vs INBX
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs INBX
Moderna, Inc MRNA $195.00 $122.98 −37% vs INBX
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs INBX
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs INBX
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs INBX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Inhibrx Biosciences, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Inhibrx Biosciences, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/INBX

Frequently asked questions

Is Inhibrx Biosciences, Inc. (INBX) overvalued or undervalued?
As of Nov 22, 2026, our estimate of fair value is $26.77 versus a price of $68.97, about 61% lower (overvalued).
What is the fair value of INBX?
Our estimate for Inhibrx Biosciences, Inc. is $26.77 (as of Nov 22, 2026), built from audited fundamentals. The current price: $68.97.
What is the quality score of INBX?
Inhibrx Biosciences, Inc. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inhibrx Biosciences, Inc. (INBX)?
We do not set a price target; the yardstick is our estimate of $26.77 (as of Nov 22, 2026). Cautious scenario $20.08, optimistic scenario $33.46. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Inhibrx Biosciences, Inc. stock forecast for 2026?
Our estimate puts fair value at $26.77, about 61% lower versus a price of $68.97 (overvalued). Cautious scenario $20.08, optimistic scenario $33.46. The calculation is refreshed regularly with new filings.
What is the revenue of Inhibrx Biosciences, Inc. (INBX)?
Inhibrx Biosciences, Inc. reported trailing-twelve-month revenue of about $2.0M (latest available figure, as of Nov 22, 2026).
What is the intrinsic value of Inhibrx Biosciences, Inc. (INBX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inhibrx Biosciences, Inc. it is $26.77 per share (as of Nov 22, 2026), against a price of $68.97.
Is Inhibrx Biosciences, Inc. stock overvalued or undervalued in 2026?
As of Nov 22, 2026, INBX trades above its calculated fair value: price $68.97, fair value $26.77, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INBX?
No. The price is what the market pays today ($68.97); the fair value is what the company's own numbers justify ($26.77). For Inhibrx Biosciences, Inc. the two are $42.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is Inhibrx Biosciences, Inc. worth?
The market values Inhibrx Biosciences, Inc. at about $1.1B (market capitalisation, as of Nov 22, 2026). Per share that is $68.97; our models calculate a fair value of $26.77 per share.
What do the bullish and bearish scenarios say about INBX?
Our models span a range for Inhibrx Biosciences, Inc.: cautious scenario $20.08, base $26.77, optimistic $33.46 per share (as of Nov 22, 2026, price $68.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Inhibrx Biosciences, Inc. (INBX)?
Balance-sheet figures for Inhibrx Biosciences, Inc. (as of Nov 22, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is INBX from its 52-week high?
Inhibrx Biosciences, Inc. trades at $68.97, about 51% below its 52-week high of $141.84 and 18% above the low of $58.39 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $26.77 is for.
Which stocks are comparable to Inhibrx Biosciences, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inhibrx Biosciences, Inc. stock attractive at the current price?
The data as of Nov 22, 2026: price $68.97, calculated fair value $26.77 (−61%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Inhibrx Biosciences, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inhibrx Biosciences, Inc. (INBX)?
The closing price on Nov 20, 2026 was $68.97. Our estimate is $26.77, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inhibrx Biosciences, Inc. right now?
The price sits above even our optimistic bull case ($33.46). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Inhibrx Biosciences, Inc.

How large is the market capitalisation of Inhibrx Biosciences, Inc. (INBX)?
The market capitalisation of Inhibrx Biosciences, Inc. is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Inhibrx Biosciences, Inc. (INBX)?
Earnings per share at Inhibrx Biosciences, Inc. are $-8.43. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Inhibrx Biosciences, Inc. (INBX)?
The return on equity (ROE) of Inhibrx Biosciences, Inc. is −1,774% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inhibrx Biosciences, Inc. (INBX)?
On an EBIT basis the return on assets of Inhibrx Biosciences, Inc. is −88.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Inhibrx Biosciences, Inc. (INBX)?
The operating margin of Inhibrx Biosciences, Inc. is −6,287% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Inhibrx Biosciences, Inc. (INBX) generate?
The free cash flow of Inhibrx Biosciences, Inc. is −$130M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Inhibrx Biosciences, Inc. (INBX) hold?
Inhibrx Biosciences, Inc. holds more cash than debt, $17.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Inhibrx Biosciences, Inc. in the live analysis

One click puts Inhibrx Biosciences, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.